Menu

Pharmaceuticals

 

 

Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

, ,

Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms June 27, 2016 – Pfizer Inc. today announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in […]

FDA approves first buprenorphine implant for treatment of opioid dependence

,

Expanded use and availability of medication-assisted treatment is a top priority of federal effort to combat opioid epidemic May 26, 2016 – The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in […]

Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study

, , , ,

Trial Studied Severe, Symptomatic Aortic Stenosis Patients at Intermediate Risk for Surgery CHICAGO, April 3, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement […]

Edwards SAPIEN XT Valve Meets Primary Endpoint In PARTNER II Trial

, , , ,

CHICAGO, April 2, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the randomized PARTNER II Trial comparing the SAPIEN XT valve to surgery in intermediate-risk patients successfully achieved its primary endpoint at two years. The results of the study […]

Merck Receives 2016 ENERGY STAR Sustained Excellence Award From U.S. Environmental Protection Agency

, ,

Company Receives EPA Honor for 11th Consecutive Year April 1, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2016 Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued improvement of […]

Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics

, , ,

Pivotal RA-BEACON Study Published in New England Journal of Medicine INDIANAPOLIS, March 31, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe […]

Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

, , , ,

Presentations Include Results from Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations March 30, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company’s broad chronic hepatitis C […]

Merck Foundation Awards Grant to American Cancer Society for Program to Improve Access to High-Quality Cancer Care in Underserved Communities

, , , ,

$1.58 Million Grant Supports Patient Navigation Program, Empowering Patients and Caregivers with Information and Support March 24, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–The Merck Foundation (the Foundation) and the American Cancer Society (ACS) announced today that the Foundation provided a grant of $1.58 million over four years to the ACS to implement a comprehensive Patient Navigation […]

Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

, , ,

In pivotal studies, most patients treated with Taltz achieved significant skin clearance (PASI 75, sPGA 0 or 1) with many achieving virtually clear (PASI 90) or completely clear (PASI 100, sPGA 0) skin at week 12 INDIANAPOLIS, March 22, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and […]

Steven Loranger Appointed To Edwards Lifesciences Board Of Directors

, ,

IRVINE, Calif., March 17, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Steven R. Loranger has been appointed to its board of directors. Loranger was most recently chief executive officer and president of leading global water technology company Xylem […]

«‹ 10 11 12 13›»